|
1
|
Argüeso P and Panjwani N: Focus on
molecules: Galectin-3. Exp Eye Res. 92:2–3. 2011. View Article : Google Scholar :
|
|
2
|
Saccon F, Gatto M, Ghirardello A,
Iaccarino L, Punzi L and Doria A: Role of galectin-3 in autoimmune
and non-autoimmune nephropathies. Autoimmun Rev. 16:34–47. 2017.
View Article : Google Scholar
|
|
3
|
Newlaczyl AU and Yu LG: Galectin-3-a
jack-of-all-trades in cancer. Cancer Lett. 313:123–128. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gong HC, Honjo Y, Nangia-Makker P, Hogan
V, Mazurak N, Bresalier RS and Raz A: The NH2 terminus of
galectin-3 governs cellular compartmentalization and functions in
cancer cells. Cancer Res. 59:6239–6245. 1999.
|
|
5
|
Menon RP and Hughes RC: Determinants in
the N-terminal domains of galectin-3 for secretion by a novel
pathway circumventing the endoplasmic reticulum-Golgi complex. Eur
J Biochem. 264:569–576. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Oliveira FL, Gatto M, Bassi N, Luisetto
R, Ghirardello A, Punzi L and Doria A: Galectin-3 in autoimmunity
and autoimmune diseases. Exp Biol Med (Maywood). 240:1019–1028.
2015. View Article : Google Scholar
|
|
7
|
Pugliese G, Iacobini C, Ricci C, Blasetti
Fantauzzi C and Menini S: Galectin-3 in diabetic patients. Clin
Chem Lab Med. 52:1413–1423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dumic J, Dabelic S and Flögel M:
Galectin-3: An open-ended story. Biochim Biophys Acta.
1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colnot C, Fowlis D, Ripoche MA, Bouchaert
I and Poirier F: Embryonic implantation in galectin 1/galectin 3
double mutant mice. Dev Dyn. 211:306–313. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim SJ, Lee HW, Gu Kang H, La SH, Choi IJ,
Ro JY, Bresalier RS, Song J and Chun KH: Ablation of galectin-3
induces 27 (KIP1)-dependent premature senescence without oncogenic
stress. Cell Death Differ. 21:1769–1779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen SC and Kuo PL: The role of galectin-3
in the kidneys. Int J Mol Sci. 17:5652016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ruvolo PP: Galectin 3 as a guardian of the
tumor microenvironment. Biochim Biophys Acta. 1863:427–437. 2016.
View Article : Google Scholar
|
|
13
|
Meijers WC, Lopez-Andrés N and de Boer RA:
Galectin-3, cardiac function, and fibrosis. Am J Pathol.
186:2232–2234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu Y, Yéléhé-Okouma M, Ea HK, Jouzeau JY
and Reboul P: Galectin-3: A key player in arthritis. Joint Bone
Spine. 84:15–20. 2017. View Article : Google Scholar
|
|
15
|
Meijers WC, van der Velde AR,
Pascual-Figal DA and de Boer RA: Galectin-3 and post-myocardial
infarction cardiac remodeling. Eur J Pharmacol. 763:115–121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lala RI, Puschita M, Darabantiu D and
Pilat L: Galectin-3 in heart failure pathology-'another brick in
the wall'. Acta Cardiol. 70:323–331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Funasaka T, Raz A and Nangia-Makker P:
Galectin-3 in angiogenesis and metastasis. Glycobiology.
24:886–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shin T: The pleiotropic effects of
galectin-3 in neuroinflammation: A review. Acta Histochem.
115:407–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meeusen JW, Johnson JN, Gray A, Wendt P,
Jefferies JL, Jaffe AS, Donato LJ and Saenger AK: Soluble ST2 and
galectin-3 in pediatric patients without heart failure. Clin
Biochem. 48:1337–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schindler EI, Szymanski JJ, Hock KG,
Geltman EM and Scott MG: Short- and long-term biologic variability
of galectin-3 and other cardiac biomarkers in patients with Stable
heart failure and healthy adults. Clin Chem. 62:360–366. 2016.
View Article : Google Scholar
|
|
21
|
Issa SF, Christensen AF, Lottenburger T,
Junker K, Lindegaard H, Hørslev-Petersen K and Junker P: Within-day
variation and influence of physical exercise on circulating
Galectin-3 in patients with rheumatoid arthritis and healthy
individuals. Scand J Immunol. 82:70–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen A, Hou W, Zhang Y, Chen Y and He B:
Prognostic value of serum galectin-3 in patients with heart
failure: A meta-analysis. Int J Cardiol. 182:168–170. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Srivatsan V, George M and Shanmugam E:
Utility of galectin-3 as a prognostic biomarker in heart failure:
Where do we stand. Eur J Prev Cardiol. 22:1096–1110. 2015.
View Article : Google Scholar
|
|
24
|
Medvedeva EA, Berezin II, Surkova EA,
Yaranov DM and Shchukin YV: Galectin-3 in patients with chronic
heart failure: Association with oxidative stress, inflammation,
renal dysfunction and prognosis. Minerva Cardioangiol. 64:595–602.
2016.PubMed/NCBI
|
|
25
|
Yu X, Sun Y, Zhao Y, Zhang W, Yang Z, Gao
Y, Cai H, Li Y, Wang Q, Bian B and Nie J: Prognostic value of
plasma galectin-3 levels in patients with coronary heart disease
and chronic heart failure. Int Heart J. 56:314–318. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coromilas E, Que-Xu EC, Moore D, Kato TS,
Wu C, Ji R, Givens R, Jorde UP, Takayama H, Naka Y, et al: Dynamics
and prognostic role of galectin-3 in patients with advanced heart
failure, during left ventricular assist device support and
following heart transplantation. BM. Cardiovasc Disord. 16:1382016.
View Article : Google Scholar
|
|
27
|
Meijers WC, Januzzi JL, deFilippi C,
Adourian AS, Shah SJ, van Veldhuisen DJ and de Boer RA: Elevated
plasma galectin-3 is associated with near-term rehospitalization in
heart failure: A pooled analysis of 3 clinical trials. Am Heart J.
167:853–860.e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kortekaas KA, Hoogslag GE, de Boer RA,
Dokter MM, Versteegh MI, Braun J, Marsan NA, Verwey HF, Delgado V,
Schalij MJ and Klautz RJ: Galectin-3 and left ventricular reverse
remodelling after surgical mitral valve repair. Eur J Heart Fail.
15:1011–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Motiwala SR, Szymonifka J, Belcher A,
Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A and Januzzi
JL: Serial measurement of galectin-3 in patients with chronic heart
failure: Results from the ProBNP outpatient tailored chronic heart
failure therapy (PROTECT) study. Eur J Heart Fail. 15:1157–1163.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koukoui F, Desmoulin F, Galinier M,
Barutaut M, Caubère C, Evaristi MF, Murat G, De Boer R, Berry M,
Smih F and Rouet P: The prognostic value of plasma galectin-3 in
chronic heart failure patients is maintained when treated with
mineralocorticoid receptor antagonists. PLoS One. 10:e01191602015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edelmann F, Holzendorf V, Wachter R, Nolte
K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen
HD, Tschöpe C, et al: Galectin-3 in patients with heart failure
with preserved ejection fraction: Results from the Aldo-DHF trial.
Eur J Heart Fail. 17:214–223. 2015. View Article : Google Scholar
|
|
32
|
Teixeira A, Arrigo M, Vergaro G,
Cohen-Solal A and Mebazaa A: Clinical benefits of natriuretic
peptides and galectin-3 are maintained in old dyspnoeic patients.
Arch Gerontol Geriatr. 68:33–38. 2017. View Article : Google Scholar
|
|
33
|
McEvoy JW, Chen Y, Halushka MK,
Christenson E, Ballantyne CM, Blumenthal RS, Christenson RH and
Selvin E: Galectin-3 and risk of heart failure and death in blacks
and whites. J Am Heart Assoc. 5(pii): e0030792016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Anand IS, Rector TS, Kuskowski M, Adourian
A, Muntendam P and Cohn JN: Baseline and serial measurements of
galectin-3 in patients with heart failure: Relationship to
prognosis and effect of treatment with valsartan in the Val-HeFT.
Eur J Heart Fail. 15:511–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van der Velde AR, Gullestad L, Ueland T,
Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ and de
Boer RA: Prognostic value of changes in galectin-3 levels over time
in patients with heart failure: Data from CORONA and COACH. Circ
Heart Fail. 6:219–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piper SE, de Courcey J, Sherwood RA,
Amin-Youssef GF and McDonagh TA: Serial galectin-3 for the
monitoring of optimally treated stable chronic heart failure: A
pilot study. Int J Cardiol. 207:279–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miller WL, Saenger AK, Grill DE, Slusser
JP, Bayes-Genis A and Jaffe AS: Prognostic value of serial
measurements of soluble suppression of tumorigenicity 2 and
Galectin-3 in ambulatory patients with chronic heart failure. J
Card Fail. 22:249–255. 2016. View Article : Google Scholar
|
|
38
|
Lala RI, Darabantiu D, Pilat L and
Puschita M: Galectin-3: A link between myocardial and arterial
stiffening in patients with acute decompensated heart failure. Arq
Bras Cardiol. 106:121–129. 2016.In English, Portuguese. PubMed/NCBI
|
|
39
|
Beltrami M, Ruocco G, Dastidar AG, Franci
B, Lucani B, Aloia E, Nuti R and Palazzuoli A: Additional value of
Galectin-3 to BNP in acute heart failure patients with preserved
ejection fraction. Clin Chim Acta. 457:99–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Atabakhshian R, Kazerouni F, Raygan F,
Amirrasouli H, Rahimipour A and Shakeri N: Assessment of the
relationship between galectin-3 and ejection fraction and
functional capacity in the patients with compensated systolic heart
failure. Int Cardiovasc Res J. 8:143–147. 2014.
|
|
41
|
Carrasco-Sánchez FJ, Aramburu-Bodas O,
Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L,
Páez-Rubio MI, Arias-Jiménez JL, Aguayo-Canela M and Pérez-Calvo
JI: Predictive value of serum galectin-3 levels in patients with
acute heart failure with preserved ejection fraction. Int J
Cardiol. 169:177–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stoltze Gaborit F, Bosselmann H, Kistorp
C, Iversen K, Kumler T, Gustafsson F, Goetze JP, Sölétormos G,
Tønder N and Schou M: Galectin 3: Association to neurohumoral
activity, echocardiographic parameters and renal function in
outpatients with heart failure. BMC Cardiovasc Disord. 16:1172016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iacoviello M, Aspromonte N, Leone M,
Paradies V, Antoncecchi V, Valle R, Caldarola P, Ciccone MM,
Gesualdo L and Serio FD: Galectin-3 Serum levels are independently
associated with microalbuminuria in chronic heart failure
outpatients. Res Cardiovasc Med. 5:e289522015. View Article : Google Scholar
|
|
44
|
Zhang R, Zhang Y, An T, Guo X, Yin S, Wang
Y, Januzzi JL, Cappola TP and Zhang J: Prognostic value of sST2 and
galectin-3 for death relative to renal function in patients
hospitalized for heart failure. Biomark Med. 9:433–441. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
AbouEzzeddine OF, Haines P, Stevens S,
Nativi-Nicolau J, Felker GM, Borlaug BA, Chen HH, Tracy RP,
Braunwald E and Redfield MM: Galectin-3 in heart failure with
preserved ejection fraction. A RELAX trial substudy
(Phosphodiesterase-5 inhibition to improve clinical status and
exercise capacity in diastolic heart failure). JACC Heart Fail.
3:245–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zamora E, Lupón J, de Antonio M, Galán A,
Domingo M, Urrutia A, Troya M and Bayes-Genis A: Renal function
largely influences Galectin-3 prognostic value in heart failure.
Int J Cardiol. 177:171–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
French B, Wang L, Ky B, Brandimarto J,
Basuray A, Fang JC, Sweitzer NK and Cappola TP: Prognostic value of
galectin-3 for adverse outcomes in chronic heart failure. J Card
Fail. 22:256–262. 2016. View Article : Google Scholar :
|
|
48
|
Yin QS, Shi B, Dong L and Bi L:
Comparative study of galectin-3 and B-type natriuretic peptide as
biomarkers for the diagnosis of heart failure. J Geriatr Cardiol.
11:79–82. 2014.PubMed/NCBI
|
|
49
|
Chen K, Jiang RJ, Wang CQ, Yin ZF, Fan YQ,
Cao JT, Han ZH, Wang Y and Song DQ: Predictive value of plasma
galectin-3 in patients with chronic heart failure. Eur Rev Med
Pharmacol Sci. 17:1005–1011. 2013.PubMed/NCBI
|
|
50
|
Gruson D, Ferracin B, Ahn SA and Rousseau
MF: Comparison of fibroblast growth factor 23, soluble ST2 and
Galectin-3 for prognostication of cardiovascular death in heart
failure patients. Int J Cardiol. 189:185–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chang YY, Chen A, Wu XM, Hsu TP, Liu LY,
Chen YH, Wu YW, Lin HJ, Hsu RB, Lee CM, et al: Comparison the
prognostic value of galectin-3 and serum markers of cardiac
extracellular matrix turnover in patients with chronic systolic
heart failure. Int J Med Sci. 11:1098–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bayes-Genis A, de Antonio M, Vila J,
Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A and Lupón J:
Head-to-head comparison of 2 myocardial fibrosis biomarkers for
long-term heart failure risk stratification: ST2 versus galectin-3.
J Am Coll Cardiol. 63:158–166. 2014. View Article : Google Scholar
|
|
53
|
Wu AH, Wians F and Jaffe A: Biological
variation of galectin-3 and soluble ST2 for chronic heart failure:
Implication on interpretation of test results. Am Heart J.
165:995–999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Feola M, Testa M, Leto L, Cardone M, Sola
M and Rosso GL: Role of galectin-3 and plasma B type-natriuretic
peptide in predicting prognosis in discharged chronic heart failure
patients. Medicine (Baltimore). 95:e40142016. View Article : Google Scholar
|
|
55
|
Zhang Y, Zhang R, An T, Huang Y, Guo X,
Yin S, Wang Y, Ji S, Lv R, Zhang J and Maisel A: The utility of
galectin-3 for predicting cause-specific death in hospitalized
patients with heart failure. J Card Fail. 21:51–59. 2015.
View Article : Google Scholar
|
|
56
|
Wang CH, Yang I, Liu MH, Hsu KH and Kuo
LT: Estimating systemic fibrosis by combining galectin-3 and ST2
provides powerful risk stratification value for patients after
acute decompensated heart failure. Cardiol J. 23:563–572.
2016.PubMed/NCBI
|
|
57
|
Zhang X, Wan Y, Chata R, Brazzale A,
Atherton JJ, Kostner K, Dimeski G and Punyadeera C: A pilot study
to demonstrate diagnostic potential of galectin-3 levels in saliva.
J Clin Pathol. 69:1100–1104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Polat V, Bozcali E, Uygun T, Opan S and
Karakaya O: Diagnostic significance of serum galectin-3 levels in
heart failure with preserved ejection fraction. Acta Cardiol.
71:191–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou K, Zhou Y, Zhao Y, Tan C, Yuan Z, Li
J, Liao X, Gu L and Zhou X: The relationship between Galectin-3 and
different patterns of ventricular geometry remodelling in aortic
valve stenosis. Heart Lung Circ. 25:371–377. 2016. View Article : Google Scholar
|
|
60
|
Sadaba JR, Martinez-Martinez E, Arrieta V,
Álvarez V, Fernández-Celis A, Ibarrola J, Melero A, Rossignol P,
Cachofeiro V and López-Andrés N: Role for Galectin-3 in calcific
aortic valve stenosis. J Am Heart Assoc. 5:pp. e0043602016,
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Arangalage D, Nguyen V, Robert T,
Melissopoulou M, Mathieu T, Estellat C, Codogno I, Huart V, Duval
X, Cimadevilla C, et al: Determinants and prognostic value of
Galectin-3 in patients with aortic valve stenosis. Heart.
102:862–868. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Maiolino G, Rossitto G, Pedon L, Cesari M,
Frigo AC, Azzolini M, Plebani M and Rossi GP: Galectin-3 predicts
long-term cardiovascular death in high-risk patients with coronary
artery disease. Arterioscler Thromb Vasc Biol. 35:725–732. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tuñón J, Blanco-Colio L, Cristóbal C,
Tarín N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D,
Lorenzo Ó, et al: Usefulness of a combination of monocyte
chemoattractant protein-1, galectin-3, and N-terminal probrain
natriuretic peptide to predict cardiovascular events in patients
with coronary artery disease. Am J Cardiol. 113:434–440. 2014.
View Article : Google Scholar
|
|
64
|
Jansen H, Koenig W, Jaensch A, Mons U,
Breitling LP, Scharnagl H, Stojakovic T, Schunkert H, Brenner H and
Rothenbacher D: Prognostic Utility of Galectin-3 for recurrent
cardiovascular events during Long-term follow-up in patients with
stable coronary heart disease: Results of the KAROLA study. Clin
Chem. 62:1372–1379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Aksan G, Gedikli Ö, Keskin K, Nar G, İnci
S, Yıldız SS, Kaplan Ö, Soylu K, Kılıçkesmez KO and Şahin M: Is
galectin-3 a biomarker, a player-or both-in the presence of
coronary atherosclerosis. J Investig Med. 64:764–770. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lepojarvi ES, Piira OP, Pääkkö E,
Lammentausta E, Risteli J, Miettinen JA, Perkiömäki JS, Huikuri HV
and Junttila MJ: Serum PINP, PIIINP, galectin-3, and ST2 as
surrogates of myocardial fibrosis and echocardiographic left
venticular diastolic filling properties. Front Physiol. 6:2002015.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gucuk Ipek E, Akin Suljevic S, Kafes H,
Basyigit F, Karalok N, Guray Y, Dinc Asarcikli L, Acar B and
Demirel H: Evaluation of galectin-3 levels in acute coronary
syndrome. Ann Cardiol Angeiol (Paris). 65:26–30. 2016. View Article : Google Scholar
|
|
68
|
George M, Shanmugam E, Srivatsan V,
Vasanth K, Ramraj B, Rajaram M, Jena A, Sridhar A, Chaudhury M and
Kaliappan I: Value of pentraxin-3 and galectin-3 in acute coronary
syndrome: A short-term prospective cohort study. Ther Adv
Cardiovasc Dis. 9:275–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Di Tano G, Caretta G, De Maria R, Parolini
M, Bassi L, Testa S and Pirelli S: Galectin-3 predicts left
ventricular remodelling after anterior-wall myocardial infarction
treated by primary percutaneous coronary intervention. Heart.
103:71–77. 2017. View Article : Google Scholar
|
|
70
|
Szadkowska I, Wlazeł RN, Migała M,
Szadkowski K, Zielińska M, Paradowski M and Pawlicki L: The
association between galectin-3 and clinical parameters in patients
with first acute myocardial infarction treated with primary
percutaneous coronary angioplasty. Cardiol J. 20:577–582. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tsai TH, Sung PH, Chang LT, Sun CK, Yeh
KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, et al: Value and
level of galectin-3 in acute myocardial infarction patients
undergoing primary percutaneous coronary intervention. J
Atheroscler Thromb. 19:1073–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Szadkowska I, Wlazel RN, Migala M,
Bajon-Laskowska K, Szadkowski K, Zielińska M, Paradowski M and
Pawlicki L: The association between galectin-3 and occurrence of
reinfarction early after first myocardial infarction treated
invasively. Biomarkers. 18:655–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Perea RJ, Morales-Ruiz M, Ortiz-Perez JT,
Bosch X, Andreu D, Borras R, Acosta J, Penela D, Prat-González S,
de Caralt TM, et al: Utility of galectin-3 in predicting
post-infarct remodeling after acute myocardial infarction based on
extracellular volume fraction mapping. Int J Cardiol. 223:458–464.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
van der Velde AR, Lexis CP, Meijers WC,
van der Horst IC, Lipsic E, Dokter MM, van Veldhuisen DJ, van der
Harst P and de Boer RA: Galectin-3 and sST2 in prediction of left
ventricular ejection fraction after myocardial infarction. Clin
Chim Acta. 452:50–57. 2016. View Article : Google Scholar
|
|
75
|
Milner TD, Viner AC, MacKinnon AC, Sethi T
and Flapan AD: Temporal expression of galectin-3 following
myocardial infarction. Acta Cardiol. 69:595–602. 2014. View Article : Google Scholar
|
|
76
|
Alturfan AA, Basar I, Emekli-Alturfan E,
Ayan F, Koldas L and Emekli N: Galectin-3 and plasma cytokines in
patients with acute myocardial infarction. Lab Med. 45:336–341.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Singsaas EG, Manhenke CA, Dickstein K and
Orn S: Circulating Galectin-3 levels are increased in patients with
ischemic heart disease, but are not influenced by acute myocardial
infarction. Cardiology. 134:398–405. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Weir RA, Petrie CJ, Murphy CA, Clements S,
Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ and
McMurray JJ: Galectin-3 and cardiac function in survivors of acute
myocardial infarction. Circ Heart Fail. 6:492–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Takemoto Y, Ramirez RJ, Yokokawa M, Kaur
K, Ponce-Balbuena D, Sinno MC, Willis BC, Ghanbari H, Ennis SR,
Guerrero-Serna G, et al: Galectin-3 regulates atrial fibrillation
remodeling and predicts catheter ablation outcomes. JACC Basic
Transl Sci. 1:143–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gurses KM, Yalcin MU, Kocyigit D, Canpinar
H, Evranos B, Yorgun H, Sahiner ML, Kaya EB, Ozer N, Tokgozoglu L,
et al: Effects of persistent atrial fibrillation on serum
galectin-3 levels. Am J Cardiol. 115:647–651. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Clementy N, Benhenda N, Piver E, Pierre B,
Bernard A, Fauchier L, Pages JC and Babuty D: Serum galectin-3
levels predict recurrences after ablation of atrial fibrillation.
Sci Rep. 6:343572016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li Wu XY, Wen SN, Nie SN, Deng JG, Bai WN,
Liu R, Tang N, Zhang RB, Du TX, et al: Plasma galectin-3 predicts
clinical outcomes after catheter ablation in persistent atrial
fibrillation patients without structural heart disease. Europace.
17:1541–1547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen D, Procter N, Goh V, Liu S, Chua SJ,
Assadi-Khansari B, Stewart S, Horowitz JD, Sverdlov AL and Ngo DT:
New onset atrial fibrillation is associated with elevated
galectin-3 levels. Int J Cardiol. 223:48–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yalcin MU, Gurses KM, Kocyigit D, Canpinar
H, Canpolat U, Evranos B, Yorgun H, Sahiner ML, Kaya EB, Hazirolan
T, et al: The association of serum galectin-3 levels with atrial
electrical and structural remodeling. J Cardiovasc Electrophysiol.
26:635–640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kornej J, Schmidl J, Ueberham L, John S,
Daneschnejad S, Dinov B, Hindricks G, Adams V, Husser D and
Bollmann A: Galectin-3 in patients with atrial fibrillation
undergoing radiofrequency catheter ablation. PLoS One. 10:pp.
e01235742015, View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Yao Y, Shen D, Chen R, Ying C, Wang C, Guo
J and Zhang G: Galectin-3 predicts left ventricular remodeling of
hypertension. J Clin Hypertens (Greenwich. 18:506–511. 2016.
View Article : Google Scholar
|
|
87
|
Pusuroglu H, Akgul O, Erturk M, Bolat I,
Tasbulak O, Ornek V, Gul M, Ozyilmaz SO, Yildirim HA, Kokturk U, et
al: Assessment of relationship between galectin-3 and ambulatory
ECG-based microvolt T-wave alternans in sustained
systolic-diastolic hypertension patients. Blood Press Monit.
21:265–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Calvier L, Legchenko E, Grimm L, Sallmon
H, Hatch A, Plouffe BD, Schroeder C, Bauersachs J, Murthy SK and
Hansmann G: Galectin-3 and aldosterone as potential tandem
biomarkers in pulmonary arterial hypertension. Heart. 102:390–396.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Agoston-Coldea L, Lupu S, Petrovai D,
Mocan T and Mousseaux E: Correlations between echocardiographic
parameters of right ventricular dysfunction and Galectin-3 in
patients with chronic obstructive pulmonary disease and pulmonary
hypertension. Med Ultrason. 17:487–495. 2015.PubMed/NCBI
|
|
90
|
Yakar Tülüce S, Tülüce K, Cil Z, Emren SV,
Akyildiz ZI and Ergene O: Galectin-3 levels in patients with
hypertrophic cardiomyopathy and its relationship with left
ventricular mass index and function. Anatol J Cardiol. 16:344–348.
2016.
|
|
91
|
Vergaro G, Del Franco A, Giannoni A,
Prontera C, Ripoli A, Barison A, Masci PG, Aquaro GD, Cohen Solal
A, Padeletti L, et al: Galectin-3 and myocardial fibrosis in
nonischemic dilated cardiomyopathy. Int J Cardiol. 184:96–100.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Franeková J, Hošková L, Sečník P Jr,
Pazderník M, Kotrbatá M, Kubíček Z and Jabor A: The role of timely
measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in
predicting prognosis and heart function after heart
transplantation. Clin Chem Lab Med. 54:339–344. 2016. View Article : Google Scholar
|
|
93
|
Franeková J, Kubíček Z, Hošková L,
Kotrbatá M, Sečník P, Kautzner J and Jabor A: Long-term biological
variability of galectin-3 after heart transplantation. Clin Chem
Lab Med. 53:119–123. 2015. View Article : Google Scholar
|
|
94
|
Grupper A, Nativi-Nicolau J, Maleszewski
JJ, Geske JR, Kremers WK, Edwards BS, Kushwaha SS and Pereira L:
Circulating galectin-3 levels are persistently elevated after heart
transplantation and are associated with renal dysfunction. JACC
Heart Fail. 4:847–856. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Casanegra AI, Stoner JA, Tafur AJ, Pereira
HA, Rathbun SW and Gardner AW: Differences in galectin-3, a
biomarker of fibrosis, between participants with peripheral artery
disease and participants with normal ankle-brachial index. Vasc
Med. 21:437–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Yan XJ, Yu GF, Jie YQ, Fan XF, Huang Q and
Dai WM: Role of galectin-3 in plasma as a predictive biomarker of
outcome after acute intracerebral hemorrhage. J Neurol Sci.
368:121–127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Opotowsky AR, Baraona F, Owumi J, Loukas
B, Singh MN, Valente AM, Wu F, Cheng S, Veldtman G, Rimm EB and
Landzberg MJ: Galectin-3 is elevated and associated with adverse
outcomes in patients with single-ventricle fontan circulation. J Am
Heart Asso. 5:e0027062016. View Article : Google Scholar
|
|
98
|
Kadoglou NP, Sfyroeras GS, Spathis A,
Gkekas C, Gastounioti A, Mantas G, Nikita KS, Karakitsos P and
Liapis CD: Galectin-3, carotid plaque vulnerability, and potential
effects of statin therapy. Eur J Vasc Endovasc Surg. 49:4–9. 2015.
View Article : Google Scholar
|
|
99
|
Liao CW, Lin YT, Wu XM, Chang YY, Hung CS,
Wu VC, Wu KD, Lin YH and TAIPAI Study Group: The relation among
aldosterone, galectin-3, and myocardial fibrosis: A prospective
clinical pilot follow-up study. J Investig Med. 64:1109–1113. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Edsfeldt A, Bengtsson E, Asciutto G, Dunér
P, Björkbacka H, Fredrikson GN, Nilsson J and Goncalves I: High
plasma levels of Galectin-3 are associated with increased risk for
stroke after carotid endarterectomy. Cerebrovasc Dis. 41:199–203.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Liu H, Liu Y, Zhao J, Liu H and He S:
Prognostic value of plasma galectin-3 levels after aneurysmal
subarachnoid hemorrhage. Brain Beha. 6:e005432016. View Article : Google Scholar
|
|
102
|
Nayor M, Wang N, Larson MG, Vasan RS, Levy
D and Ho JE: Circulating Galectin-3 is associated with
cardiometabolic disease in the community. J Am Heart Asso. 5(pii):
e0023472015. View Article : Google Scholar
|
|
103
|
Nishiyama J, Kobayashi S, Ishida A,
Nakabayashi I, Tajima O, Miura S, Katayama M and Nogami H:
Up-regulation of galectin-3 in acute renal failure of the rat. Am J
Pathol. 157:815–823. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ji F, Zhang S, Jiang X, Xu Y, Chen Z, Fan
Y and Wang W: Diagnostic and prognostic value of galectin-3, serum
creatinine, and cystatin C in chronic kidney diseases. J Clin Lab
Ana. Oct 11–2017.Epub ahead of print. View Article : Google Scholar
|
|
105
|
O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS,
Levy D and Fox CS: Elevated galectin-3 precedes the development of
CKD. J Am Soc Nephrol. 24:1470–1477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Bansal N, Katz R, Seliger S, DeFilippi C,
Sarnak MJ, Delaney JA, Christenson R, de Boer IH, Kestenbaum B,
Robinson-Cohen C, et al: Galectin-3 and Soluble ST2 and kidney
function decline in older adults: The cardiovascular health study
(CHS). Am J Kidney Dis. 67:994–996. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Drechsler C, Delgado G, Wanner C, Blouin
K, Pilz S, Tomaschitz A, Kleber ME, Dressel A, Willmes C, Krane V,
et al: Galectin-3, renal function, and clinical outcomes: Results
from the LURIC and 4D studies. J Am Soc Nephrol. 26:2213–2221.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Gurel OM, Yilmaz H, Celik TH, Cakmak M,
Namuslu M, Bilgiç AM, Bavbek N, Akcay A and Eryonucu B: Galectin-3
as a new biomarker of diastolic dysfunction in hemodialysis
patients. Herz. 40:788–794. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Yilmaz H, Gurel OM, Celik HT, Bozkurt A,
Yildirim ME, Bilgic I, Bilgic MA, Bavbek N and Akcay A:
Relationship of galectin-3 to left ventricular geometry and
hypertrophy in chronic hemodialysis patients. Herz. 40:702–708.
2015. View Article : Google Scholar
|
|
110
|
Ozkan G, Ulusoy S, Mentese A, Guvercin B,
Karahan SC, Yavuz A, Altay DU and Ocal M: Can be galectin-3 a novel
marker in determining mortality in hemodialysis patients. Clin
Biochem. 48:768–773. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Hogas S, Schiller A, Voroneanu L,
Constantinescu D, Timar R, Cianga P, Siriopol D, Bob F, Cianga C,
Onofriescu M, et al: Predictive value for Galectin 3 and
cardiotrophin 1 in hemodialysis patients. Angiology. 67:854–859.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Schwerg M, Eilers B, Wienecke A, Baumann
G, Laule M, Knebel F, Stangl K and Stangl V: Galectin-3 and
prediction of therapeutic response to renal sympathetic
denervation. Clin Exp Hypertens. 38:399–403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Bing Z, Lal P, Lu S, Ziober A and
Tomaszewski JE: Role of carbonic anhydrase IX, α-methylacyl
coenzyme a racemase, cytokeratin 7, and galectin-3 in the
evaluation of renal neoplasms: A tissue microarray
immunohistochemical study. Ann Diagn Pathol. 17:58–62. 2013.
View Article : Google Scholar
|
|
114
|
Kaneko N, Gotoh A, Okamura N, Matsuo E,
Terao S, Watanabe M, Yamada Y, Hamami G, Nakamura T, Ikekita M, et
al: Potential tumor markers of renal cell carcinoma: α-enolase for
postoperative follow up, and galectin-1 and galectin-3 for primary
detection. Int J Urol. 20:530–535. 2013. View Article : Google Scholar
|
|
115
|
von Klot CA, Kramer MW, Peters I,
Hennenlotter J, Abbas M, Scherer R, Herrmann TR, Stenzl A, Kuczyk
MA, Serth J and Merseburger AS: Galectin-1 and Galectin-3 mRNA
expression in renal cell carcinoma. BMC Clin Pathol. 14:152014.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Straube T, Elli AF, Greb C, Hegele A,
Elsässer HP, Delacour D and Jacob R: Changes in the expression and
subcellular distribution of galectin-3 in clear cell renal cell
carcinoma. J Exp Clin Cancer Res. 30:892011. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Sakaki M, Fukumori T, Fukawa T, Elsamman
E, Shiirevnyamba A, Nakatsuji H and Kanayama HO: Clinical
significance of Galectin-3 in clear cell renal cell carcinoma. J
Med Invest. 57:152–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Tang W, Huang C, Tang C, Xu J and Wang H:
Galectin-3 may serve as a potential marker for diagnosis and
prognosis in papillary thyroid carcinoma: A meta-analysis. Onco
Targets Ther. 9:455–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Manivannan P, Siddaraju N, Jatiya L and
Verma SK: Role of pro-angiogenic marker galectin-3 in follicular
neoplasms of thyroid. Indian. J Biochem Biophys. 49:392–394.
2012.
|
|
120
|
Mataraci EA, Ozgüven BY and Kabukcuoglu F:
Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic
and nonneoplastic thyroid lesions. Pol J Pathol. 63:58–64.
2012.PubMed/NCBI
|
|
121
|
Matesa-Anić D, Moslavac S, Matesa N, Cupić
H and Kusić Z: Intensity and distribution of immunohistochemical
expression of galectin-3 in thyroid neoplasms. Acta Clin Croat.
51:237–241. 2012.
|
|
122
|
Sumana BS, Shashidhar S and Shivarudrappa
AS: Galectin-3 immunohistochemical expression in thyroid neoplasms.
J Clin Diagn Res. 9:EC07–EC11. 2015.PubMed/NCBI
|
|
123
|
Papale F, Cafiero G, Grimaldi A, Marino G,
Rosso F, Mian C, Barollo S, Pennelli G, Sorrenti S, De Antoni E and
Barbarisi A: Galectin-3 expression in thyroid fine needle cytology
(t-FNAC) uncertain cases: Validation of molecular markers and
technology innovation. J Cell Physiol. 228:968–974. 2013.
View Article : Google Scholar
|
|
124
|
Salajegheh A, Dolan-Evans E, Sullivan E,
Irani S, Rahman MA, Vosgha H, Gopalan V, Smith RA and Lam AK: The
expression profiles of the galectin gene family in primary and
metastatic papillary thyroid carcinoma with particular emphasis on
galectin-1 and galectin-3 expression. Exp Mol Pathol. 96:212–218.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Al-Sharaky DR and Younes SF: Sensitivity
and specificity of Galectin-3 and Glypican-3 in
Follicular-patterned and other thyroid neoplasms. J Clin Diagn Res.
10:EC06–EC10. 2016.PubMed/NCBI
|
|
126
|
Yilmaz E, Karsidag T, Tatar C and Tüzün S:
Serum Galectin-3: Diagnostic value for papillary thyroid carcinoma.
Ulus Cerrahi Derg. 31:192–196. 2015.PubMed/NCBI
|
|
127
|
Paunovic I, Isic T, Havelka M, Tatic S,
Cvejic D and Savin S: Combined immunohistochemistry for thyroid
peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis
of thyroid tumors. APMIS. 120:368–379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Abd-El Raouf SM and Ibrahim TR:
Immunohistochemical expression of HBME-1 and galectin-3 in the
differential diagnosis of follicular-derived thyroid nodules.
Pathol Res Pract. 210:971–978. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Trimboli P, Guidobaldi L, Amendola S,
Nasrollah N, Romanelli F, Attanasio D, Ramacciato G, Saggiorato E,
Valabrega S and Crescenzi A: Galectin-3 and HBME-1 improve the
accuracy of core biopsy in indeterminate thyroid nodules.
Endocrine. 52:39–45. 2016. View Article : Google Scholar
|
|
130
|
Durry MF, Miskad UA, Leiwakabessy WN and
Cangara MH: Diagnostic value of galectin-3 and hector battifora
mesothelial epitope (hbme)-1 as a marker for malignancy in the
diagnosis of thyroid lesions. Patholog. 48(Suppl 1): S122–S123.
2016.
|
|
131
|
Das DK, Al-Waheeb SK, George SS, Haji BI
and Mallik MK: Contribution of immunocytochemical stainings for
galectin-3, CD44, and HBME1 to fine-needle aspiration cytology
diagnosis of papillary thyroid carcinoma. Diagn Cytopathol.
42:498–505. 2014. View Article : Google Scholar
|
|
132
|
Karaarslan S, Yurum FN, Kumbaraci BS, Pala
EE, Sivrikoz ON, Akyildiz M and Bugdayci MH: The role of
parafibromin, Galectin-3, HBME-1, and Ki-67 in the differential
diagnosis of parathyroid tumors. Oman Med J. 30:421–427. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Wang O, Wang CY, Shi J, Nie M, Xia WB, Li
M, Jiang Y, Guan H, Meng XW and Xing XP: Expression of Ki-67,
galectin-3, fragile histidine triad, and parafibromin in malignant
and benign parathyroid tumors. Chin Med J (Engl. 125:2895–2901.
2012.
|
|
134
|
Selemetjev SA, Savin SB, Paunovic IR,
Tatic SB and Cvejic D: Changes in the expression pattern of
apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during
progression of thyroid malignancy and their clinical significance.
Wien Klin Wochenschr. 127:337–344. 2015. View Article : Google Scholar
|
|
135
|
Lee YM and Lee JB: Prognostic value of
epidermal growth factor receptor, 53 and galectin-3 expression in
papillary thyroid carcinoma. J Int Med Res. 41:825–834. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Nechifor-Boilă A, Cătană R, Loghin A, Radu
TG and Borda A: Diagnostic value of HBME-1, CD56, Galectin-3 and
Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors
of uncertain malignant potential. Rom J Morphol Embryol. 55:49–56.
2014.
|
|
137
|
Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li
Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19,
thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive
behavior of papillary thyroid carcinoma. Int J Clin Exp Med.
7:2304–2308. 2014.PubMed/NCBI
|
|
138
|
Gweon HM, Kim JA, Youk JH, Hong SW, Lim
BJ, Yoon SO, Park YM and Son EJ: Can galectin-3 be a useful marker
for conventional papillary thyroid microcarcinoma. Diagn
Cytopathol. 44:103–107. 2016. View Article : Google Scholar
|
|
139
|
Wang X, Yuegao, Bai L, Ibrahim MM, Ma W,
Zhang J, Huang Y, Wang B, Song L and Tang J: Evaluation of annexin
A7, Galectin-3 and Gelsolin as possible biomarkers of
hepatocarcinoma lymphatic metastasis. Biomed Pharmacother.
68:259–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Serizawa N, Tian J, Fukada H, Baghy K,
Scott F, Chen X, Kiss Z, Olson K, Hsu D, Liu FT, et al: Galectin 3
regulates HCC cell invasion by RhoA and MLCK activation. Lab
Invest. 95:1145–1156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ulu M, Alacacioglu A, Yuksel E, Pamukk BO,
Bozkaya G, Ari A, Yuksel A, Sop G and Alacacioglu I: Prognostic
significance of serum galectin-3 levels in patients with
hepatocellular cancer and chronic viral hepatitis. Saudi J
Gastroenterol. 21:47–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Eisa NH, Ebrahim MA, Ragab M, Eissa LA and
El-Gayar AM: Galectin-3 and matrix metalloproteinase-9: Perspective
in management of hepatocellular carcinoma. J Oncol Pharm Pract.
21:323–330. 2015. View Article : Google Scholar
|
|
143
|
Jiang SS, Weng DS, Wang QJ, Pan K, Zhang
YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, et al: Galectin-3 is
associated with a poor prognosis in primary hepatocellular
carcinoma. J Transl Med. 12:2732014. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Balan V, Wang Y, Nangia-Makker P, Kho D,
Bajaj M, Smith D, Heilbrun L, Raz A and Heath E: Galectin-3: A
possible complementary marker to the PSA blood test. Oncotarget.
4:542–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Nakajima K, Heilbrun LK, Hogan V, Smith D,
Heath E and Raz A: Positive associations between galectin-3 and PSA
levels in prostate cancer patients: A prospective clinical study-I.
Oncotarget. 7:82266–82272. 2016.PubMed/NCBI
|
|
146
|
Araujo-Filho JL, Melo-Junior MR, Beltrão
EI, de Lima LR, Antunes CB and de Carvalho LB Jr:
Immunochemiluminescent detection of galectin-3 in tumoral tissue
from prostate. Int J Clin Exp Pathol. 6:1861–1867. 2013.PubMed/NCBI
|
|
147
|
Knapp JS, Lokeshwar SD, Vogel U,
Hennenlotter J, Schwentner C, Kramer MW, Stenzl A and Merseburger
AS: Galectin-3 expression in prostate cancer and benign prostate
tissues: Correlation with biochemical recurrence. World J Urol.
31:351–358. 2013. View Article : Google Scholar
|
|
148
|
Xie L, Ni WK, Chen XD, Xiao MB, Chen BY,
He S, Lu CH, Li XY, Jiang F and Ni RZ: The expressions and clinical
significances of tissue and serum galectin-3 in pancreatic
carcinoma. J Cancer Res Clin Oncol. 138:1035–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Jiang K, Lawson D, Cohen C and Siddiqui
MT: Galectin-3 and PTEN expression in pancreatic ductal
adenocarcinoma, pancreatic neuroendocrine neoplasms and
gastrointestinal tumors on fine-needle aspiration cytology. Acta
Cytol. 58:281–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Barrow H, Guo X, Wandall HH, Pedersen JW,
Fu B, Zhao Q, Chen C, Rhodes JM and Yu LG: Serum galectin-2, -4,
and -8 are greatly increased in colon and breast cancer patients
and promote cancer cell adhesion to blood vascular endothelium.
Clin Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Barrow H, Rhodes JM and Yu LG:
Simultaneous determination of serum galectin-3 and -4 levels
detects metastases in colorectal cancer patients. Cell Oncol
(Dordr). 36:9–13. 2013. View Article : Google Scholar
|
|
152
|
Shimura T, Shibata M, Gonda K, Nakajima T,
Chida S, Noda M, Suzuki S, Nakamura I, Ohki S and Takenoshita S:
Association between circulating galectin-3 levels and the
immunological, inflammatory and nutritional parameters in patients
with colorectal cancer. Biomed Rep. 5:203–207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Petrovic S, Radosavljevic GD, Pantic J,
Jovanovic I, Jankovic N and Arsenijevic N: Circulating and tissue
galectin-1 and galectin-3 in colorectal carcinoma: Association with
clinicopathological parameters, serum CEA, IL-17 and IL23. J BUON.
21:941–949. 2016.PubMed/NCBI
|
|
154
|
Zhang H, Luo M, Liang X, Wang D, Gu X,
Duan C, Gu H, Chen G, Zhao X, Zhao Z and Liu C: Galectin-3 as a
marker and potential therapeutic target in breast cancer. PLoS One.
9:e1034822014. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Koo JS and Jung W: Clinicopathlogic and
immunohistochemical characteristics of triple negative invasive
lobular carcinoma. Yonsei Med J. 52:89–97. 2011. View Article : Google Scholar :
|
|
156
|
Yamaki S, Fujii T, Yajima R, Hirakata T,
Yamaguchi S, Fujisawa T, Tsutsumi S, Asao T, Yanagita Y, Iijima M
and Kuwano H: Clinicopathological significance of decreased
galectin-3 expression and the long-term prognosis in patients with
breast cancer. Surg Today. 43:901–905. 2013. View Article : Google Scholar
|
|
157
|
Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC,
Woodward WA, Buchholz TA, Acklin K, Ramirez K, Hafley M, Alt E, et
al: Low expression of galectin-3 is associated with poor survival
in node-positive breast cancers and mesenchymal phenotype in breast
cancer stem cells. Breast Cancer Res. 18:972016. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
El Gendy H, Madkour B, Abdelaty S, Essawy
F, Khattab D, Hammam O, El Kholy A and Nour HH: Galectin 3 for the
diagnosis of bladder cancer. Arab J Urol. 12:178–181. 2014.
View Article : Google Scholar
|
|
159
|
Gendy HE, Madkour B, Abdelaty S, Essawy F,
Khattab D, Hammam O and Nour HH: Diagnostic and prognostic
significance of serum and tissue Galectin 3 expression in patients
with carcinoma of the bladder. Curr Urol. 7:185–190. 2014.
View Article : Google Scholar
|
|
160
|
Cheng D, Liang B and Li Y: Serum
galectin-3 as a potential marker for gastric cancer. Med Sci Monit.
21:755–760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Leal MF, Calcagno DQ, Chung J, de Freitas
VM, Demachki S, Assumpção PP, Chammas R, Burbano RR and Smith MC:
Deregulated expression of annexin-A2 and galectin-3 is associated
with metastasis in gastric cancer patients. Clin Exp Med.
15:415–420. 2015. View Article : Google Scholar
|
|
162
|
Tas F, Bilgin E, Tastekin D, Erturk K and
Duranyildiz D: Clinical significance of serum Galectin-3 levels in
gastric cancer patients. J Gastrointest Cancer. 47:182–186. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Gomes TS, Oshima CT, Forones NM, De
Oliveira Lima F and Ribeiro DA: Expression of galectin-3 in gastric
adenocarcinoma. Indian J Med Res. 140:69–76. 2014.PubMed/NCBI
|
|
164
|
Gao N, Yu WZ, Guo NJ, Wang XX and Sun JR:
Clinical significance of galectin-3 in patients with adult acute
myeloid leukemia: A retrospective cohort study with long-term
follow-up and formulation of risk scoring system. Leuk Lymphoma.
58:1394–1402. 2017. View Article : Google Scholar
|
|
165
|
Samura B: Galectin-3 as a prognostic
biomarker in patients with Non-Hodgkin lymphoma. Georgian Med News.
7–11. 2015.PubMed/NCBI
|
|
166
|
Lambropoulou M, Deftereou TE, Kynigopoulos
S, Patsias A, Anagnostopoulos C, Alexiadis G, Kotini A, Tsaroucha
A, Nikolaidou C, Kiziridou A, et al: Co-expression of galectin-3
and CRIP-1 in endometrial cancer: Prognostic value and patient
survival. Med Oncol. 33:82016. View Article : Google Scholar
|
|
167
|
Zhou X, Jing J, Peng J, Mao W, Zheng Y,
Wang D, Wang X, Liu Z and Zhang X: Expression and clinical
significance of galectin-3 in osteosarcoma. Gene. 546:403–407.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Aggarwal S, Sharma SC and Das SN:
Galectin-1 and galectin-3: Plausible tumour markers for oral
squamous cell carcinoma and suitable targets for screening
high-risk population. Clin Chim Acta. 442:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Righi A, Morandi L, Leonardi E, Farnedi A,
Marucci G, Sisto A, Frank G, Faustini-Fustini M, Zoli M, Mazzatenta
D, et al: Galectin-3 expression in pituitary adenomas as a marker
of aggressive behavior. Hum Pathol. 44:2400–2409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Yang LP, Jiang S, Liu JQ, Miao XY and Yang
ZL: Up-regulation of galectin-3 and Sambucus nigra agglutinin
binding site is associated with invasion, metastasis and
poor-progression of the gallbladder adenocarcinoma.
Hepatogastroenterology. 59:2089–2094. 2012.PubMed/NCBI
|
|
171
|
Zhang L, Wang P, Qin Y, Cong Q, Shao C, Du
Z, Ni X, Li P and Ding K: RN1, a novel galectin-3 inhibitor,
inhibits pancreatic cancer cell growth in vitro and in vivo via
blocking galectin-3 associated signaling pathways. Oncogene.
36:1297–1308. 2017. View Article : Google Scholar
|
|
172
|
Yang Y, Zhou Z, He S, Fan T, Jin Y, Zhu X,
Chen C, Zhang ZR and Huang Y: Treatment of prostate carcinoma with
(galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil
conjugates. Biomaterials. 33:2260–2271. 2012. View Article : Google Scholar
|
|
173
|
Guha P, Kaptan E, Bandyopadhyaya G,
Kaczanowska S, Davila E, Thompson K, Martin SS, Kalvakolanu DV,
Vasta GR and Ahmed H: Cod glycopeptide with picomolar affinity to
galectin-3 suppresses T-cell apoptosis and prostate cancer
metastasis. Proc Natl Acad Sci USA. 110:5052–5057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Mirandola L, Yu Y, Cannon MJ, Jenkins MR,
Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA and
Chiriva-Internati M: Galectin-3 inhibition suppresses drug
resistance, motility, invasion and angiogenic potential in ovarian
cancer. Gynecol Oncol. 135:573–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Calvier L, Martinez-Martinez E, Miana M,
Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P and
López-Andrés N: The impact of galectin-3 inhibition on
aldosterone-induced cardiac and renal injuries. JACC Heart Fail.
3:59–67. 2015. View Article : Google Scholar
|
|
176
|
Vergaro G, Prud'homme M, Fazal L, Merval
R, Passino C, Emdin M, Samuel JL, Cohen Solal A and Delcayre C:
Inhibition of Galectin-3 pathway prevents isoproterenol-induced
left ventricular dysfunction and fibrosis in mice. Hypertension.
67:606–612. 2016.PubMed/NCBI
|
|
177
|
Martinez-Martinez E, Calvier L, Rossignol
P, Rousseau E, Fernández-Celis A, Jurado-López R, Laville M,
Cachofeiro V and López-Andrés N: Galectin-3 inhibition prevents
adipose tissue remodelling in obesity. Int J Obes (Lond).
40:1034–1038. 2016. View Article : Google Scholar
|
|
178
|
MacKinnon AC, Liu X, Hadoke PW, Miller MR,
Newby DE and Sethi T: Inhibition of galectin-3 reduces
atherosclerosis in apolipoprotein E-deficient mice. Glycobiology.
23:654–663. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Delaine T, Collins P, MacKinnon A, Sharma
G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh
BA, et al: Galectin-3-binding glycomimetics that strongly reduce
bleomycin-induced lung fibrosis and modulate intracellular glycan
recognition. Chembiochem. 17:1759–1770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Rajput VK, MacKinnon A, Mandal S, Collins
P, Blanchard H, Leffler H, Sethi T, Schambye H, Mukhopadhyay B and
Nilsson UJ: A Selective Galactose-coumarin-derived Galectin-3
inhibitor demonstrates involvement of Galectin-3-glycan
interactions in a pulmonary fibrosis model. J Med Chem.
59:8141–8147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Traber PG and Zomer E: Therapy of
experimental NASH and fibrosis with galectin inhibitors. PLoS One.
8:e834812013. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Harrison SA, Marri SR, Chalasani N, Kohli
R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA,
Lawitz E, et al: Randomised clinical study: GR-MD-02, a galectin-3
inhibitor, vs. placebo in patients having non-alcoholic
steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther.
44:1183–1198. 2016. View Article : Google Scholar : PubMed/NCBI
|
